Beyond Histology: A Single-cell Perspective on Intestinal Transplantation

In this issue of Transplantation, Karmi et al1 presented a compelling case series that expands our understanding of the intestinal allograft’s cellular and molecular landscape during the initial first 6 mo posttransplantation. By applying single-cell mRNA sequencing to serial ileal biopsies from 3 transplant recipients, the authors unravel the dynamics of both donor and recipient cell compartments—from baseline through mild, moderate, and severe rejection episodes.1 Their findings shed new light on why certain allografts may be accepted or recovered, whereas others succumb to therapy-resistant rejection.1 Intestinal transplantation (ITx) remains the definitive therapy for patients with end-stage intestinal failure who have exhausted or cannot tolerate parenteral nutrition.2,3 Despite notable advances in surgical techniques and immunosuppressive treatment, the 5-y graft survival rate for ITx continues to lag behind that of other solid organ transplants, at roughly 50%–60%.2,4,5 This heightened rate of graft loss is commonly attributed to the high incidence of severe allograft rejection and the consequent need for strong generalized immunosuppression, which in turn can precipitate life-threatening complications, such as graft-versus-host disease, posttransplant lymphoproliferative disorder, kidney failure, and opportunistic infections.4,5 The small intestine is notably immunogenic, harboring an extensive array of immune cells capable of mounting rapid alloimmune responses.6 Consequently, numerous research efforts have focused on identifying reliable rejection biomarkers to enable earlier and more targeted immunosuppressive interventions.7,8 However, the complex interactions among donor tissue-resident cells, infiltrating recipient immune cells, and multiagent immunosuppression remain difficult to dissect with traditional methodologies.6 Karmi et al1 addressed these challenges by using longitudinal single-cell transcriptomics and genotype-based cell origin assignment to monitor donor-recipient chimerism and molecular changes within the intestinal graft. Their study design showcases 3 distinct clinical trajectories: a “successful transplant,” which experienced only a brief episode of mild rejection; a “recovered transplant,” initially developing moderate rejection but responding to intensified immunosuppression; and a “rejected transplant,” ultimately succumbing to severe, therapy-resistant rejection.1 Karmi et al1 presented several noteworthy observations. First, all grafts exhibited recipient immune cell infiltration within 2 wk, confirming the rapid onset of mucosal chimerism. Notably, the graft that ultimately experienced severe, therapy-resistant rejection showed a swift influx of recipient T and B cells within the first month post-ITx, potentially foreshadowing a severe rejection episode. Second, epithelial outcomes varied significantly: although the rejected graft developed irreversible epithelial loss consistent with treatment-resistant severe rejection pathology, the successful and recovered grafts retained their epithelial integrity, suggesting that preserving this barrier compartment may be critical for preventing severe rejection and graft loss. Third, important nuances in immunosuppression emerged: although anti-thymocyte globulin (thymoglobulin) is frequently used as T cell–depleting induction regimen in ITx,9 it failed to completely deplete donor T cells in any of the allografts; additionally, rescue treatments with infliximab and alemtuzumab did not halt the rejection process in the rejected allograft, suggesting a complex role for treatment-refractory T cells and other immune cell subsets in steroid resistance. Finally, the authors detected molecular “early warnings” in the rejected allograft, where transcriptomic data revealed apoptosis, interferon-driven inflammation, and dysregulated barrier function pathways (ρ GTPase signaling) well before severe rejection was evident histologically—highlighting their potential utility as predictive biomarkers for earlier intervention.1 A hallmark of this investigation is the demonstration that molecular indicators of severe rejection can emerge before overt histopathological changes become apparent. Although conventional surveillance continues to rely heavily on biopsy interpretations,2 these findings suggest that single-cell signatures may refine how we detect and characterize early-stage rejection.1 In the future, earlier recognition of key molecular pathways—such as interferon signaling or epithelial apoptosis—could prompt preemptive adjustments to immunosuppression, potentially preventing severe allograft rejection. Furthermore, the study highlights that not all adaptive immune cell subsets respond uniformly.1 Tissue-resident donor T cells appear more resistant to thymoglobulin-mediated depletion, while recipient T cells may expand in a way that indicates subsequent rejection. With larger patient cohorts, single-cell analysis could pinpoint which immunological subpopulations—such as B cells, memory Th1 or Th17 cells, or innate lymphoid cells—best predict rejection and may serve as actionable targets for more precise immunotherapeutic strategies. Although the work by Karmi et al1 offered interesting mechanistic insights, several areas warrant further exploration. First, although these findings are intriguing, they come from a small cohort of 3 patients, underscoring the need for larger, multicenter, longitudinal studies to validate the identified molecular signatures and clarify the timing and nature of immunological changes. Second, layering single-cell transcriptomics with additional “omics” approaches—including proteomics, metabolomics, and advanced immunophenotyping—could deepen our systems-level understanding of graft–host interactions in ITx. Finally, in view of the significant heterogeneity in T- and B-cell infiltration, exploring gut-specific immunosuppressive strategies such as vedolizumab or other lymphocyte trafficking inhibitors may reduce systemic toxicity while offering more targeted immunosuppression. In conclusion, the demonstration of divergent clinical trajectories in a small cohort by Karmi et al1 underscores the heterogeneity of immune mechanisms driving ITx outcomes. Their single-cell approach reveals dynamic shifts in donor-recipient chimerism and pinpoints key molecular signals that foreshadow rejection. By elucidating these processes at high resolution, this study provides the blueprint for larger biomarker validation studies, paving the way for more rational, targeted, and ultimately more effective immunosuppressive regimens—advancing the field toward personalized medicine in ITx.